|
注册号: Registration number: |
ChiCTR2300069904 |
|
最近更新日期: Date of Last Refreshed on: |
2025-07-07 17:56:00 |
|
注册时间: Date of Registration: |
2023-03-29 00:00:00 |
|
注册号状态: |
预注册 |
|
Registration Status: |
Prospective registration |
|
注册题目: |
构建中国糖尿病共享门诊的优化试验研究(SMART) |
|
Public title: |
Construction of the Shared Medical Appointment for Diabetes (SMART) in China: an Optimization Trial |
|
注册题目简写: |
|
|
English Acronym: |
|
|
研究课题的正式科学名称: |
构建中国糖尿病共享门诊的优化试验研究 |
|
Scientific title: |
Construction of the Shared Medical Appointment for Diabetes (SMART) in China: an Optimization Trial |
|
研究课题代号(代码): Study subject ID: |
|
|
在二级注册机构或其它机构的注册号: The registration number of the Partner Registry or other register: |
|
申请注册联系人: |
蔡毅媛 |
研究负责人: |
蔡毅媛 |
|
Applicant: |
Yiyuan Cai |
Study leader: |
Yiyuan Cai |
|
申请注册联系人电话: Applicant telephone: |
+86 153 2900 9316 |
研究负责人电话:
Study leader's |
+86 153 2900 9316 |
|
申请注册联系人传真 : Applicant Fax: |
研究负责人传真: Study leader's fax: |
||
|
申请注册联系人电子邮件: Applicant E-mail: |
caiyiyuan@gmc.edu.cn |
研究负责人电子邮件: Study leader's E-mail: |
caiyiyuan@gmc.edu.cn |
|
申请单位网址(自愿提供): Applicant website(voluntary supply): |
研究负责人网址(自愿提供): Study leader's website(voluntary supply): |
||
|
申请注册联系人通讯地址: |
贵州省贵安新区安康大道6号贵州医科大学云漫湖校区 |
研究负责人通讯地址: |
贵州省贵安新区安康大道6号贵州医科大学云漫湖校区 |
|
Applicant address: |
Yunman Lake Campus of Guizhou Medical University, 6 Ankang Ave., Gui'an New District, Guizhou, China |
Study leader's address: |
Yunman Lake Campus of Guizhou Medical University, 6 Ankang Ave., Gui'an New District, Guizhou, China |
|
申请注册联系人邮政编码: Applicant postcode: |
研究负责人邮政编码: Study leader's postcode: |
||
|
申请人所在单位: |
贵州医科大学公共卫生与健康学院 |
||
|
Applicant's institution: |
School of Public Health, Guizhou Medical University |
||
|
研究负责人所在单位: |
贵州医科大学公共卫生与健康学院 |
||
|
Affiliation of the Leader: |
School of Public Health, Guizhou Medical University |
||
|
是否获伦理委员会批准: |
是 |
||
|
Approved by ethic committee: |
Yes |
||
|
伦理委员会批件文号: Approved No. of ethic committee: |
2024伦审第 (231) 号和2023伦审第 (4) 号 |
伦理委员会批件附件: Approved file of Ethical Committee: |
查看附件View |
|
批准本研究的伦理委员会名称: |
贵州医科大学人体试验伦理委员会 |
||
|
Name of the ethic committee: |
Human Trial Ethics Committee of Guizhou Medical University |
||
|
伦理委员会批准日期: Date of approved by ethic committee: |
2024-09-18 00:00:00 | ||
|
伦理委员会联系人: |
汤磊 |
||
|
Contact Name of the ethic committee: |
Lei Tang |
||
|
伦理委员会联系地址: |
贵州省贵安新区安康大道6号贵州医科大学云漫湖校区 |
||
|
Contact Address of the ethic committee: |
Yunman Lake Campus of Guizhou Medical University, 6 Ankang Ave., Gui'an New District, Guizhou, China |
||
|
伦理委员会联系人电话: Contact phone of the ethic committee: |
+86 851 8858 2671 |
伦理委员会联系人邮箱: Contact email of the ethic committee: |
|
|
研究实施负责(组长)单位: |
贵州医科大学公共卫生与健康学院 |
||||||||||||||||||||||
|
Primary sponsor: |
School of Public Health, Guizhou Medical University |
||||||||||||||||||||||
|
研究实施负责(组长)单位地址: |
贵州省贵安新区安康大道6号 |
||||||||||||||||||||||
|
Primary sponsor's address: |
6 Ankang Ave., Gui'an New District, Guizhou, China |
||||||||||||||||||||||
|
试验主办单位(项目批准或申办者): Secondary sponsor: |
|
||||||||||||||||||||||
|
经费或物资来源: |
国家自然科学基金(批准号72164005) |
||||||||||||||||||||||
|
Source(s) of funding: |
The China National Natural Science Foundation (grant 72164005) |
||||||||||||||||||||||
|
研究疾病: |
糖尿病 |
||||||||||||||||||||||
|
Target disease: |
diabetes |
||||||||||||||||||||||
|
研究疾病代码: |
|
||||||||||||||||||||||
|
Target disease code: |
|
||||||||||||||||||||||
|
研究类型: |
干预性研究 |
||||||||||||||||||||||
|
Study type: |
Interventional study |
||||||||||||||||||||||
|
研究所处阶段: |
其它 | ||||||||||||||||||||||
|
Study phase: |
N/A |
||||||||||||||||||||||
|
研究设计: |
随机平行对照 |
||||||||||||||||||||||
|
Study design: |
Parallel |
||||||||||||||||||||||
|
研究目的: |
1. 确定在中国基层医疗卫生服务机构中采用和实施糖尿病共享门诊的潜在障碍; 2. 在可预见的实施障碍的条件下,确定最佳的共享门诊组件,实现最佳健康结果。 |
||||||||||||||||||||||
|
Objectives of Study: |
1. To identify the potential barriers to adopting and implementing SMA for diabetes in the primary care settings of China; 2. To identify the optimal configuration of SMA components that can potentially achieve the best health outcomes under the conditions of tackling foreseeable implementation barriers. |
||||||||||||||||||||||
|
药物成份或治疗方案详述: |
|
||||||||||||||||||||||
|
Description for medicine or protocol of treatment in detail: |
|
||||||||||||||||||||||
|
纳入标准: |
|||||||||||||||||||||||
|
Inclusion criteria |
|||||||||||||||||||||||
|
排除标准: |
1. 针对医生:拒绝参与糖尿病共享门诊试点者,将被排除。 2. 针对患者:采用C-MMSE对认知功能进行评价,评分小于18分者,或无法自行前往医疗机构参与门诊服务者,或拒绝参与者将被排除。 3. 针对利益相关者:拒绝受访者将被排除。 |
||||||||||||||||||||||
|
Exclusion criteria: |
1. SMA providers who refuse to participate in the SMA trial will be excluded. 2. Patient participants: People with cognitive and physical disabilities that prevent participation in the group clinical consultation will be excluded. The cognitive status will be assessed using the Chinese Mini-Mental State Examination (C-MMSE), with patients scoring 23 or lower being excluded. Participants will be asked about any physical limitations that prevent them from coming to the clinic individually, and those who report such constraints or refuse to participate will be excluded. 3. Stakeholders who rejected respondents will be excluded. |
||||||||||||||||||||||
|
研究实施时间: Study execute time: |
从 From 2023-04-01 00:00:00至 To 2026-03-31 00:00:00 |
征募观察对象时间: Recruiting time: |
从 From 2023-04-15 00:00:00 至 To 2025-09-30 00:00:00 |
|
干预措施: Interventions: |
|
|
研究实施地点: Countries of recruitment and research settings: |
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
测量指标: Outcomes: |
|
|
采集人体标本:
Collecting sample(s)
|
|
|
征募研究对象情况: Recruiting status: |
正在进行 Recruiting |
年龄范围: Participant age: |
|
||||||
|
性别: |
男女均可 |
Gender: |
Both |
||||||
|
随机方法(请说明由何人用什么方法产生随机序列): |
一名独立于SMART项目数据收集的统计人员将完成干预分配。分配给每个机构的SMA 干预包类型将遵循R软件MOST软件包(第0.1.0版)中的“随机分配生成器(Version 0.1.0)”生成的随机数字表对参与机构进行随机分组。 |
||||||||
|
Randomization Procedure (please state who generates the random number sequence and by what method): |
A statistician independent of the SMART program data collection will complete the intervention assignment. The type of SMA IP assigned to each institution will follow the random number table generated by the "Random Assignment Generator(Version 0.1.0)" in the MOST package (Version 0.1.0) of the R software. |
||||||||
|
是否公开试验完成后的统计结果: Calculated Results after the Study Completed public access: |
公开/Public |
|
盲法: |
无 |
|
Blinding: |
None |
|
试验完成后的统计结果(上传文件): |
|
|
Calculated Results after
|
|
|
是否共享原始数据: IPD sharing |
是Yes |
|
共享原始数据的方式(说明:请填入公开原始数据日期和方式,如采用网络平台,需填该网络平台名称和网址): |
研究公开发表后1年,可通过联系研究者 caiyiyuan_cyy@qq.com 征得同意后共享原始数据。 |
|
The way of sharing IPD”(include metadata and protocol, If use web-based public database, please provide the url): |
One year after the publication of the research, the original data can be shared with consent by contacting the researcher at caiyiyuan_cyy@qq.com. |
|
数据采集和管理(说明:数据采集和管理由两部分组成,一为病例记录表(Case Record Form, CRF),二为电子采集和管理系统(Electronic Data Capture, EDC),如ResMan即为一种基于互联网的EDC: |
将采用问卷星和REDCap电子方式采集数据;用REDCap管理数据。 |
|
Data collection and Management (A standard data collection and management system include a CRF and an electronic data capture: |
Wenjuanxin and RedCap will be used for data collection and RedCap will be used for data management. |
|
数据与安全监察委员会: Data and Safety Monitoring Committee: |
有/Yes |